LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

The TROPION-Breast01 phase III study evaluated Dato-DXd,a TROP2-directed ADC for treating inoperable or metastatic hormone ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...

AZ and Daiichi Sankyo have more than 20 trials evaluating the efficacy and safety of Dato-DXd across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC), and HR-positive ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

AstraZeneca is specifically focusing its drug, known by the shorthand Dato-DXd, on patients whose breast cancer tests positive for estrogen and progesterone receptors, but negative for the HER2 gene.

Our peak revenue estimate is USD 11 billion. Dato-DXd is a clinical-stage TROP2 ADC that is being developed for lung cancer, triple negative breast cancer, and other cancer types. The company has ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

The triple-negative breast cancer market dynamics are expected to change in the coming years with the upcoming availability of new treatment options and increasing healthcare spending across the ...

A new arm of a clinical trial will investigate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer. A patient received a dose of the novel menin inhibitor, ziftomenib ...